Compare Amylx Pharmaceuticals Inc (AMLX) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amylx Pharmaceuticals Inc vs MINISO Group Holding Ltd — how do they compare? Amylx Pharmaceuticals Inc trades at $17.77 (market cap $1.98B), while MINISO Group Holding Ltd trades at $11.47 (market cap $3.51B). The key difference: MINISO Group Holding Ltd is the larger of the two by market cap, and MINISO Group Holding Ltd pays a 5.65% dividend while Amylx Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMLX | MNSO | |
|---|---|---|
Market Cap | $1.98B | $3.51B |
Sector | Health | Technology |
52-Week High | $18.70 | $26.63 |
52-Week Low | $7.64 | $11.30 |
Enterprise Value | $1.70B | $4.17B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMLX trades at $17.77, down 3.32% today, with a bullish technical signal from moving averages and strong analyst support. The company is in a pivotal phase with key Phase 3 data for avexitide expected in Q3 2026, targeting a potential 2027 launch. Financially, it shows significant losses with negative ROE and ROA, but cash flow from financing activities provides runway. Recent news highlights clinical progress and conference presentations, alongside ongoing class action settlement discussions.
The outlook hinges on successful clinical trial outcomes, particularly avexitide's Phase 3 readout, which could drive substantial upside toward the $30.50 consensus price target. However, high execution risk, persistent cash burn, and legal overhangs pose threats to near-term stability. Investor sentiment remains cautiously optimistic given the 90.9% buy rating from analysts, but the stock is speculative until profitability milestones are achieved.
MNSO trades at $11.79, up 2.79% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating expectations with EPS of $0.591, and announced a HK$2 billion share repurchase program on June 29, 2026. Revenue grew to $21.44 billion in 2025, with a net income margin of 8.98% and a P/E ratio of 12, indicating potential undervaluation.
The outlook is mixed: analyst consensus is 75% buy with growth potential from overseas expansion, but risks include margin compression and recent earnings misses. The stock's current price near the lower end of its 52-week range suggests caution amid bearish technical trends, though fundamentals support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amylx Pharmaceuticals Inc
Amylyx Pharmaceuticals is a biopharmaceutical firm focused on developing therapies for rare diseases. Its pipeline includes treatments for conditions like post-bariatric hypoglycemia and congenital hyperinsulinism.
Read more on AMLX →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
